what does it mean when the baseline is such a high death rate of aGVHD patients, around 85%?
Do you really need a randomised controlled study using a placebo.
All this constant sniping is designed to undermine trust in MSB's management, rather than looking at the serious deficiencies in the FDA.
There's plenty of evidence of the latter, including how only now are they consulting over their policy on stem cell therapies.
Trying to bury MSB with rubbish.
Ann: Mesoblast Type A Meeting with FDA, page-364
-
- There are more pages in this discussion • 211 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.084B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.8¢ | 93.5¢ | $4.207M | 4.417M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 42268 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 48002 | 3 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |